Gelteq Limited Ordinary Shares (GELS)

This article provides an earnings forecast for Gelteq Ltd (GELS), focusing on future EPS and revenue growth estimates. It includes current stock performance, market capitalization, and a comparison with peer pharmaceutical companies. The financial forecasting section indicates data available for EPS, Revenue, Net Profit, and EBIT, last updated on August 6, 2026.

This article provides a brief valuation analysis for Gelteq Ltd (GELS), focusing on its stock performance and key financial ratios like P/E, P/B, and P/CF. The data indicates that relevant information for these valuation metrics has not yet been disclosed by the company. Gelteq Ltd (GELS) closed at $0.587, down 11.20%, with a market capitalization of $6.29M.

This article provides an earnings forecast for Gelteq Ltd (GELS), focusing on its future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and different analytical dimensions like valuation, price momentum, and institutional confidence. The article also lists peer comparisons with other pharmaceutical companies and indicates that the financial forecasting data was updated on July 27, 2026.

This article from TradingKey provides an overview of Gelteq Ltd (GELS)'s financial health, focusing on profitability and balance sheet analysis. It highlights key financial figures such as the closing stock price, market cap, and P/E TTM. The piece serves as a preliminary financial snapshot for potential investors.

This article details the shareholder structure of Gelteq Ltd (GELS), listing both major individual and corporate shareholders, along with a breakdown by shareholder type such as individual investors, corporations, and hedge funds. It also provides institutional shareholding data over several quarters and recent shareholder activity with changes in holdings for key investors and institutions like Two Sigma Investments and Wedbush Securities.